{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:01:13Z","timestamp":1784858473530,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hepatic arterial infusion pump (HAIP) chemotherapy is an effective treatment for patients with unresectable intrahepatic cholangiocarcinoma (iCCA). HAIP chemotherapy requires a catheter inserted in the gastroduodenal artery and a subcutaneous pump. The catheter can be placed using an open or robotic approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This study aimed to compare perioperative outcomes of robotic versus open HAIP placement in patients with unresectable iCCA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed patients with unresectable iCCA included in the PUMP-II trial from January 2020 to September 2022 undergoing robotic or open HAIP placement at Amsterdam UMC, Erasmus MC, and UMC Utrecht. The primary outcome was time to functional recovery (TTFR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 22 robotic and 28 open HAIP placements were performed. The median TTFR was 2\u00a0days after robotic placement versus 5 days after open HAIP placement (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001). One patient (4.5%) in the robotic group underwent a conversion to open because of a large bulky tumor leaning on the hilum immobilizing the liver. Postoperative complications were similar\u201436% (8\/22) after robotic placement versus 39% (11\/28) after open placement (<jats:italic>p<\/jats:italic>\u00a0=\u00a01.000). The median length of hospital stay was shorter in the robotic group\u20143 versus 5 days (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001). All 22 robotic patients initiated HAIP chemotherapy post-surgery, i.e. 93% (26\/28) in the open group (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.497). The median time to start HAIP chemotherapy was 14 versus 18 days (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.153).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Robotic HAIP placement in patients with unresectable iCCA is a safe and effective procedure and is associated with a significantly shorter TTFR and hospital stay than open HAIP placement.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-024-15127-w","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T14:01:45Z","timestamp":1710770505000},"page":"4022-4029","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Robotic Versus Open Hepatic Arterial Infusion Pump Placement for Unresectable Intrahepatic Cholangiocarcinoma"],"prefix":"10.1245","volume":"31","author":[{"given":"Britte H. E. A.","family":"Ten Haaft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick W. J. J.","family":"van Dorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Rousian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Pilz da Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeland F.","family":"de Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris I.","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Groot Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Hagendoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger-Jan","family":"Swijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"Suppl 1","key":"15127_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19\u201331.","journal-title":"Liver Int."},{"key":"15127_CR2","unstructured":"Integraal Kankercentrum Nederland (IKNL). NKR-cijfers. 1990\u20132023. Available at: https:\/\/www.cijfersoverkanker.nl"},{"issue":"1","key":"15127_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"I Endo","year":"2008","unstructured":"Endo I, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84\u201396.","journal-title":"Ann Surg."},{"issue":"2","key":"15127_CR4","first-page":"200","volume":"112","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, et al. Advanced intrahepatic cholangiocarcinoma: post-hoc analysis of the ABC-01, -02 and -03 clinical trials. J Natl Cancer Inst. 2020;112(2):200\u201310.","journal-title":"J Natl Cancer Inst."},{"issue":"8","key":"15127_CR5","doi-asserted-by":"publisher","first-page":"EVIDoa200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence. 2022;1(8):EVIDoa200015.","journal-title":"NEJM Evidence."},{"issue":"4","key":"15127_CR6","first-page":"589","volume":"75","author":"NB Ackerman","year":"1974","unstructured":"Ackerman NB. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery. 1974;75(4):589\u201396.","journal-title":"Surgery."},{"issue":"5","key":"15127_CR7","first-page":"969","volume":"30","author":"C Breedis","year":"1954","unstructured":"Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969\u201377.","journal-title":"Am J Pathol."},{"issue":"2","key":"15127_CR8","first-page":"176","volume":"10","author":"WD Ensminger","year":"1983","unstructured":"Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983;10(2):176\u201382.","journal-title":"Semin Oncol."},{"issue":"4","key":"15127_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.soc.2008.04.009","volume":"17","author":"DS Dizon","year":"2008","unstructured":"Dizon DS, Schwartz J, Kemeny N. Regional chemotherapy: a focus on hepatic artery infusion for colorectal cancer liver metastases. Surg Oncol Clin N Am. 2008;17(4):759\u201371.","journal-title":"Surg Oncol Clin N Am."},{"issue":"1","key":"15127_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","volume":"6","author":"A Cercek","year":"2020","unstructured":"Cercek A, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):60\u20137.","journal-title":"JAMA Oncol."},{"issue":"3\u20134","key":"15127_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000324704","volume":"80","author":"NE Kemeny","year":"2011","unstructured":"Kemeny NE, et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology. 2011;80(3\u20134):153\u20139.","journal-title":"Oncology."},{"issue":"9","key":"15127_CR12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","volume":"20","author":"WR Jarnagin","year":"2009","unstructured":"Jarnagin WR, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol. 2009;20(9):1589\u201395.","journal-title":"Ann Oncol."},{"issue":"5","key":"15127_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.hpb.2016.12.015","volume":"19","author":"M Qadan","year":"2017","unstructured":"Qadan M, et al. Robotic hepatic arterial infusion pump placement. HPB (Oxford). 2017;19(5):429\u201335.","journal-title":"HPB (Oxford)."},{"issue":"3","key":"15127_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/jso.24325","volume":"114","author":"M Dhir","year":"2016","unstructured":"Dhir M, et al. Robotic assisted placement of hepatic artery infusion pump is a safe and feasible approach. J Surg Oncol. 2016;114(3):342\u20137.","journal-title":"J Surg Oncol."},{"key":"15127_CR15","unstructured":"PUMP2 Protocol. Available at: https:\/\/www.chemopomp.nl\/verwijzers\/pump-2-studie."},{"issue":"1","key":"15127_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/SLA.0000000000002979","volume":"269","author":"T de Rooij","year":"2019","unstructured":"de Rooij T, et al. Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial. Ann Surg. 2019;269(1):2\u20139.","journal-title":"Ann Surg."},{"issue":"1","key":"15127_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-017-2423-4","volume":"19","author":"T de Rooij","year":"2018","unstructured":"de Rooij T, et al. Minimally invasive versus open pancreatoduodenectomy (LEOPARD-2): study protocol for a randomized controlled trial. Trials. 2018;19(1):1.","journal-title":"Trials."},{"issue":"1","key":"15127_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jamcollsurg.2005.03.019","volume":"201","author":"PJ Allen","year":"2005","unstructured":"Allen PJ, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201(1):57\u201365.","journal-title":"J Am Coll Surg."},{"issue":"3","key":"15127_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.amjsurg.2021.03.066","volume":"222","author":"S Partelli","year":"2021","unstructured":"Partelli S, et al. Evaluation of cost-effectiveness among open, laparoscopic and robotic distal pancreatectomy: a systematic review and meta-analysis. Am J Surg. 2021;222(3):513\u201320.","journal-title":"Am J Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15127-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15127-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15127-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T13:08:51Z","timestamp":1715087331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15127-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["15127"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15127-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"21 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Rutger-Jan Swijnenburg receives fees from Intuitive Surgical for proctorship activities, which are all transferred to the AMC Medical Research Foundation. Bas Groot Koerkamp: Tricumed (Germany) provided the pumps for the trial. Britte H.E.A. ten Haaft, Stijn Franssen, Roderick W.J.J. van Dorst, Merve Rousian, Gabriela Pilz da Cunha, Roeland F. de Wilde, Joris I. Erdmann, and Jeroen Hagendoorn have no disclosures to declare in relation to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}